|
Sex.
|
|
Male:female
|
0.0803
|
|
Age (years) ≤ 69 vs ≥ 70
|
0.8002
|
|
Symptomatic level Cervical vs thoracic vs lumbosacral
|
0.1603
|
|
Pathology Adenocarcinoma vs non-adenocarcinoma
|
0.0263*
|
|
Tokuhashi score
|
|
General condition
|
|
Poor vs good
|
0.0019*
|
|
Moderate vs good
|
0.0321*
|
|
Number of extraspinal bone metastases foci
|
0.9604
|
|
Number of metastases in the vertebral body
|
0.1388
|
|
Metastases to the major internal organs
|
0.6994
|
|
Paralysis (spinal cord palsy)
|
0.0279*
|
|
Total score ≤ 8 vs 9–10
|
0.1542
|
|
ALP 400 IU/L ≥ or <
|
0.0961
|
|
CEA 120 ng/ml ≥ or <
|
0.5189
|
|
Molecular target drug, use (for ≥ 1 month) or not
|
0.0093*
|
|
Bone-modifying agent, use or not
|
0.8650
|
